<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680651</url>
  </required_header>
  <id_info>
    <org_study_id>AGMCC1318 (29BRC18.0123)</org_study_id>
    <nct_id>NCT03680651</nct_id>
  </id_info>
  <brief_title>Frequency and Type of Genetic Abnormalities Found in Antenatal Corpus Callosum Malformation</brief_title>
  <acronym>AGMCC1318</acronym>
  <official_title>Frequency and Type of Genetic Abnormalities Found in Antenatal Corpus Callosum Malformation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corpus callosum malformation (CCM) is the most frequently detected cerebral defect diagnosed
      in the prenatal setting. The most common CCM is corpus callosum agenesis (CCA) which is found
      in 2 to 3% of patients presenting with intellectual disability.

      When CCM is diagnosed, the risk of chromosomal disorder is estimated to be 16%, be it
      aneuploidy such as trisomy 18, trisomy 13 or mosaic trisomy 8, or a chromosome structure
      anomaly, copy number variation or more complex rearrangement In France, since 2013
      oligoarray-based comparative genomic hybridization (aCGH) analysis is performed in the
      prenatal period for most malformations after approval by a multidisciplinary prenatal
      diagnosis ethics committee (Centre Pluridisciplinaire de Diagnostic Prénatal, CPDPN) .
      However, to date only a few studies have been published which report recurrent Copy Number
      Variations (CNV) associated with CCM and estimate the risk for a chromosomal disorder, thus
      making counseling difficult in this context of prenatal diagnosis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 18, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>frequency of chromosomal abnormalities</measure>
    <time_frame>6 months</time_frame>
    <description>The main objective is to describe the frequency of chromosomal abnormalities associated with a prenatal diagnosis of corpus callosum agenesis in the hope of improving genetic counseling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of chromosomal abnormalities</measure>
    <time_frame>6 months</time_frame>
    <description>Describe the type of chromosomal abnormalities associated with a prenatal diagnosis of corpus callosum agenesis and thus identify recurrent copy number variations.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Corpus Callosum Malformation</condition>
  <condition>Prenatal Disorder</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Fetuses with prenatal diagnosis of corpus callosum malformation and antenatal molecular
        analysis by array CGH performed
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prenatal diagnosis of corpus callosum malformation, isolated or not, between
             01/01/2013, and 31/05/2018

          -  Fetal DNA available

          -  Mother's informed consent obtained

        Exclusion Criteria:

          -  No amniocentesis performed

          -  Refusing to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne-Hélène Saliou, MD</last_name>
    <phone>02 29 02 00 12</phone>
    <email>anne-helene.saliou@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte Caille-Benigni, Resident</last_name>
    <phone>06 50 22 85 93</phone>
    <email>charlotte.caillebenigni@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Hélène Saliou, MD</last_name>
      <phone>02 29 02 00 12</phone>
      <email>anne-helene.saliou@chu-brest.fr</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Caille-Benigni, Resident</last_name>
      <phone>06 50 22 85 93</phone>
      <email>charlotte.caillebenigni@chu-brest.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>September 20, 2018</last_update_submitted>
  <last_update_submitted_qc>September 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agenesis of Corpus Callosum</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

